🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Glomerulosclerosis, Focal Segmental

A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) NCT05583942NA2 sites📍 New Hyde Park📍 Philadelphia Northwell Health · Tests: trascutaneous auricular vagus nerve stimulation, Sham device China Kidney Patient Trials Network NCT05036850n/a1 site📍 Beijing George (Beijing) Clinical Research Co. Ltd. Nephrotic Syndrome Study Network NCT01209000n/a44 sites📍 Los Angeles📍 Palo Alto📍 San Francisco University of Michigan · Tests: Kidney Biopsy Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. NCT05505500n/a1 site📍 Ann Arbor University of Michigan · Tests: Interview Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease NCT05650619n/a1 site📍 Ann Arbor University of Michigan · Tests: Biospecimen collection, Data collection Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis NCT07010250n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris taVNS for FRNS in Children NCT05588063NA2 sites📍 New Hyde Park📍 Philadelphia Northwell Health · Tests: Transcutaneous auricular vagus nerve stimulation, Sham device An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases NCT06664814Phase 21 site📍 Bethesda National Human Genome Research Institute (NHGRI) · Tests: ManNAc Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases NCT07614477Phase 22 sites📍 Beijing📍 Tianjin Everest Medicines (China) Co.,Ltd. · Tests: EVER001 Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome NCT06334692n/a1 site📍 Ranica Mario Negri Institute for Pharmacological Research · Tests: In-house ELISA, and ELISA kits from "DBA Italy" (Abbexa). A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis NCT07499700Phase 2, Phase 31 site📍 Beijing Bio-Thera Solutions · Tests: BAT4406F, Placebos KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis NCT03929887n/a6 sites📍 Chuncheon📍 Daegu📍 Seoul Seoul National University Hospital · Tests: Kidney Biopsy A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) NCT07220083Phase 3316 sites📍 Alabaster📍 Huntsville📍 Surprise Boehringer Ingelheim · Tests: BI 764198, Placebo Raman Spectroscopy Diagnosis of Kidney Diseases NCT06760845n/a1 site📍 Jinan Zunsong Wang · Tests: Imaging Time A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis NCT07213960Phase 2, Phase 32 sites📍 Chicago📍 New York Apellis Pharmaceuticals, Inc. · Tests: APL2, Placebo A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB NCT05183646Phase 3220 sites📍 Birmingham📍 Phoenix📍 Phoenix Dimerix Bioscience Pty Ltd · Tests: DMX-200, Placebo Proteinuria in Pre and Post Transplant NCT01094327n/a1 site📍 Miami University of Miami A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) NCT07268638Phase 230 sites📍 Chula Vista📍 Garden Grove📍 Los Angeles Akebia Therapeutics · Tests: Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B) Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System NCT04065438NA10 sites📍 Loma Linda📍 Loma Linda📍 Wilmington Kaneka Medical America LLC · Tests: LIPOSORBER® LA-15 ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank NCT06162546n/a1 site📍 Vienna Christoph Aufricht · Tests: Registry The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) NCT03949972n/a12 sites📍 Cologne📍 Aachen📍 Berlin Prof. Dr. Paul Brinkkoetter · Tests: Biosampling Study of WAL0921 in Patients With Glomerular Kidney Diseases NCT06466135Phase 250 sites📍 Los Angeles📍 Denver📍 Tamarac Walden Biosciences · Tests: WAL0921, Placebo Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children NCT02235857NA12 sites📍 Loma Linda📍 Los Angeles📍 Wilmington Kaneka Medical America LLC · Tests: LIPOSORBER® LA-15 System SLIT ABS: Study on Patients With Autoimmune Podocytopathy NCT07516964NA14 sites📍 Rochester📍 München📍 Bagno a Ripoli Meyer Children's Hospital IRCCS · Tests: Serum and renal tissue analysis A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease NCT06500702Phase 279 sites📍 Birmingham📍 Orange📍 San Francisco Sanofi · Tests: frexalimab, brivekimig, rilzabrutinib, placebo Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases NCT05003986Phase 247 sites📍 Los Angeles📍 Wilmington📍 Miami Travere Therapeutics, Inc. · Tests: Sparsentan, Sparsentan, Sparsentan INS, B Cells and Microbiota NCT04924712n/a2 sites📍 Nantes📍 La Roche-sur-Yon Nantes University Hospital · Tests: Measurement of blood immune populations and microbiota distribution. INSIGHT (Insight Into Nephrotic Syndrome) NCT01605266n/a4 sites📍 Brampton📍 Hamilton📍 Scarborough Village The Hospital for Sick Children A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects NCT05942625Phase 11 site📍 Nanjing Hansoh BioMedical R&D Company · Tests: HS-10390 tablet, Placebo tablet NEPTUNE Match Study NCT04571658NA16 sites📍 Atlanta📍 Chicago📍 Kansas City University of Michigan · Tests: Communication
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy